首页> 外文期刊>International journal of molecular medicine >Adenosine A(2A) receptor activation reverses hypoxia-induced rat pulmonary artery smooth muscle cell proliferation via cyclic AMP-mediated inhibition of the SDF1-CXC4 signaling pathway
【24h】

Adenosine A(2A) receptor activation reverses hypoxia-induced rat pulmonary artery smooth muscle cell proliferation via cyclic AMP-mediated inhibition of the SDF1-CXC4 signaling pathway

机译:腺苷A(2A)受体激活通过循环型AMP介导的SDF1-CXC4信号通路抑制逆转缺氧诱导的大鼠肺动脉平滑肌细胞增殖

获取原文
获取原文并翻译 | 示例
       

摘要

The occurrence and the subsequent development of pulmonary arterial hypertension (PAH) involve complicated mechanisms. Of these, the proliferation of pulmonary artery smooth muscle cells (PASMCs) has been indicated to be closely associated with its progression. Therefore, therapeutic methods targeting PASMCs to inhibit proliferation is an effective method for alleviating PAH. The present study was designed to determine the role of the adenosine A(2A) receptor (A(2A) receptor) in hypoxia-induced rat PASMC (RPASMC) proliferation. Primary RPASMCs were isolated from the pulmonary artery of adult male SD rats, cultured and used for the following experiments. The mRNA level and protein expression of CXCR4 were measured by reverse transcription-quantitative polymerase chain reaction and western blot analysis, respectively. The cell proliferation of RPASMCs was measured using a cell proliferation assay kit. In the present study, it was demonstrated that the proliferation of RPASMCs was partially mediated by activation of the stromal cell-derived factor 1 (SDF1)-CXC chemokine receptor 4 (CXCR4) axis under hypoxic conditions. In addition, SDF1- alone upregulated the mRNA and protein expression levels of CXCR4, and stimulated the proliferation of RPASMCs. The protein expression of CXCR4 and the cell proliferation were markedly inhibited by application of A(2A) receptor agonist CGS21680 or cyclic adenosine monophosphate (cAMP) under hypoxic conditions or treatment with SDF1- and was reversed by the A(2A) receptor antagonist SCH58261 or 8-bromoadenosine-3,5-cyclic monophosphorothioate. These results demonstrated that the inhibition of SDF1-CXC4 signaling by the activation of A(2A) receptor and subsequent increase in the level of cAMP may be a potential method to ameliorate PAH.
机译:肺动脉高血压(PAH)的发生和随后的发育涉及复杂的机制。其中,已表明肺动脉平滑肌细胞(PASMCS)的增殖与其进展密切相关。因此,靶向PASMC以抑制增殖的治疗方法是减轻PAH的有效方法。本研究旨在确定腺苷A(2A)受体(A(2A)受体)在缺氧诱导的大鼠PASMC(RPASMC)增殖中的作用。从成年雄性SD大鼠的肺动脉中分离出原发性RPASMC,培养并用于以下实验。通过逆转录定量聚合酶链反应和Western印迹分析分别测量CXCR4的mRNA水平和蛋白质表达。使用细胞增殖测定试剂盒测量RPASMCs的细胞增殖。在本研究中,证明RPASMCs的增殖部分通过在缺氧条件下激活基质细胞衍生因子1(SDF1)-CXC趋化因子受体4(CXCR4)轴来部分介导。此外,单独的SDF1-单独上调CXCR4的mRNA和蛋白表达水平,并刺激RPASMC的增殖。通过在缺氧条件下施用(2A)受体激动剂CGS21680或环状腺苷一磷酸盐(CAMP)明显抑制CXCR4和细胞增殖的蛋白质表达或用SDF1-处理,并由A(2A)受体拮抗剂SCH58261反转8-溴纳米苷-3,5-环状二磷酸酯。这些结果表明,通过激活(2A)受体的SDF1-CXC4信号传导和随后的阵营水平的增加可能是改善PAH的潜在方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号